Efficacy of esketamine for the treatment of postpartum depression and pain control following cesarean section: a randomized, double-blind, controlled clinical trial

• Published in: BMC anesthesiology Vol. 24; no. 1; p. 52
• Main Authors: Li, Shurong, Zhuo, Zhifang, Li, Renwei, Guo, Kaikai
• Format: Journal Article
• Language: English
• Published: England BioMed Central Ltd 06.02.2024; BioMed Central; BMC
• Subjects: Analgesia; Anesthesia; Antidepressants; Brain-derived neurotrophic factor; Care and treatment; Cesarean section; Cesarean Section - adverse effects; Clinical trials; Depression, Postpartum - drug therapy; Esketamine; Female; Humans; Intravenous administration; Ketamine; Pain; Pain - drug therapy; Pain Management; Pain perception; Pain, Postoperative - drug therapy; Patient-controlled intravenous analgesia; Patients; Pharmaceuticals; Postpartum; Postpartum depression; Postpartum women; Pregnancy; Questionnaires; Sufentanil; Tropisetron; China; Beijing China; United States > US; Esketamine; Postpartum depression; Patient-controlled intravenous analgesia; Postpartum women; Cesarean section
• ISSN: 1471-2253; 1471-2253
• DOI: 10.1186/s12871-024-02436-6

Postpartum depression (PPD) following a cesarean delivery is a frequently seen complication. Despite the prophylactic effects of ketamine, the impact of esketamine on PPD in women undergoing cesarean section remains uncertain. This study aimed to assess the effectiveness of esketamine as an adjunct to patient-controlled intravenous analgesia (PCIA) in preventing PPD in women undergoing caesarean section. A total of 275 parturients undergoing caesarean section and subsequent patient-controlled intravenous analgesia (PCIA) were randomly assigned to receive either the control treatment (sufentanil 2 µg/kg + tropisetron 10 mg) or the experimental treatment with additional esketamine (1.5 mg/kg). The primary outcome measured was the incidence of postpartum depression (PPD), classified by Edinburgh Postnatal Depression Scale (EPDS) scores equal to or greater than 13 indicating PPD. Secondary outcomes included cumulative sufentanil consumption during specific time periods (0-24 h, 24-48 h, and 0-48 h) after the surgical procedure and numerical rating scale (NRS) scores at rest and during movements. The final analysis included a total of 246 postpartum women who had undergone caesarean delivery. On postoperative day 42, the incidence of depression among the control group was 17.6%, which was significantly higher compared to the esketamine group with a rate of 8.2% (P = 0.02). The EPDS scores also showed a significant difference between the two groups, with a mean score of 9.02 ± 2.21 in the control group and 6.87 ± 2.14 in the esketamine group (p < 0.0001). In terms of pain management, the esketamine group showed lower sufentanil consumption in the 0-24 h (42.5 ± 4.58 µg vs. 50.15 ± 5.47 µg, P = 0.04) and 0-48 h (87.40 ± 9.51 µg vs. 95.10 ± 9.36 µg, P = 0.04) postoperative periods compared to the control group. Differences in movement were also observed between the two groups at 24 and 48 h after the cesarean Sect. (3.39 ± 1.57 vs. 4.50 ± 0.80, P = 0.02; 2.43 ± 0.87 vs. 3.56 ± 0.76, P = 0.02). It is worth noting that the frequency of side effects observed in both groups was comparable. Esketamine at a dose of 1.5 mg/kg, when used as a supplement in PCIA, has been shown to significantly reduce the occurrence of PPD within 42 days. Additionally, it has been found to decrease cumulative consumption of sufentanil over a 48-hour period following cesarean operation, all without increasing the rate of adverse effects. Registered in the Chinese Clinical Trial Registry (ChiCTR2200067054) on December 26, 2022.